Klinik und Poliklinik für Innere Medizin II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Institute of Molecular Immunology and Experimental Oncology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Gastroenterology. 2019 Jan;156(1):203-217.e20. doi: 10.1053/j.gastro.2018.09.053. Epub 2018 Oct 6.
Cells in pancreatic ductal adenocarcinoma (PDAC) undergo autophagy, but its effects vary with tumor stage and genetic factors. We investigated the consequences of varying levels of the autophagy related 5 (Atg5) protein on pancreatic tumor formation and progression.
We generated mice that express oncogenic Kras in primary pancreatic cancer cells and have homozygous disruption of Atg5 (A5;Kras) or heterozygous disruption of Atg5 (A5;Kras), and compared them with mice with only oncogenic Kras (controls). Pancreata were analyzed by histology and immunohistochemistry. Primary tumor cells were isolated and used to perform transcriptome, metabolome, intracellular calcium, extracellular cathepsin activity, and cell migration and invasion analyses. The cells were injected into wild-type littermates, and orthotopic tumor growth and metastasis were monitored. Atg5 was knocked down in pancreatic cancer cell lines using small hairpin RNAs; cell migration and invasion were measured, and cells were injected into wild-type littermates. PDAC samples were obtained from independent cohorts of patients and protein levels were measured on immunoblot and immunohistochemistry; we tested the correlation of protein levels with metastasis and patient survival times.
A5;Kras mice, with reduced Atg5 levels, developed more tumors and metastases, than control mice, whereas A5;Kras mice did not develop any tumors. Cultured A5;Kras primary tumor cells were resistant to induction and inhibition of autophagy, had altered mitochondrial morphology, compromised mitochondrial function, changes in intracellular Ca oscillations, and increased activity of extracellular cathepsin L and D. The tumors that formed in A5;Kras mice contained greater numbers of type 2 macrophages than control mice, and primary A5;Kras tumor cells had up-regulated expression of cytokines that regulate macrophage chemoattraction and differentiation into M2 macrophage. Knockdown of Atg5 in pancreatic cancer cell lines increased their migratory and invasive capabilities, and formation of metastases following injection into mice. In human PDAC samples, lower levels of ATG5 associated with tumor metastasis and shorter survival time.
In mice that express oncogenic Kras in pancreatic cells, heterozygous disruption of Atg5 and reduced protein levels promotes tumor development, whereas homozygous disruption of Atg5 blocks tumorigenesis. Therapeutic strategies to alter autophagy in PDAC should consider the effects of ATG5 levels to avoid the expansion of resistant and highly aggressive cells.
胰腺导管腺癌(PDAC)中的细胞会发生自噬,但自噬的作用因肿瘤阶段和遗传因素而异。我们研究了自噬相关蛋白 5(Atg5)蛋白水平的变化对胰腺肿瘤形成和进展的影响。
我们生成了在原代胰腺癌细胞中表达致癌性 Kras 且 Atg5 纯合缺失(A5;Kras)或杂合缺失(A5;Kras)的小鼠,并将其与仅表达致癌性 Kras 的小鼠(对照)进行比较。通过组织学和免疫组织化学分析胰腺。分离原代肿瘤细胞,并进行转录组、代谢组、细胞内钙、细胞外组织蛋白酶活性以及细胞迁移和侵袭分析。将这些细胞注射到野生型同窝仔鼠中,监测原位肿瘤生长和转移情况。使用短发夹 RNA 敲低胰腺癌细胞系中的 Atg5;测量细胞迁移和侵袭,然后将细胞注射到野生型同窝仔鼠中。从独立的 PDAC 患者队列中获得 PDAC 样本,并在免疫印迹和免疫组织化学上测量蛋白水平;我们检测了蛋白水平与转移和患者生存时间的相关性。
与对照组相比,Atg5 水平降低的 A5;Kras 小鼠形成了更多的肿瘤和转移灶,而 A5;Kras 小鼠则未形成任何肿瘤。培养的 A5;Kras 原代肿瘤细胞对自噬的诱导和抑制具有抗性,线粒体形态发生改变,线粒体功能受损,细胞内 Ca 振荡发生变化,细胞外组织蛋白酶 L 和 D 的活性增加。在 A5;Kras 小鼠中形成的肿瘤比对照组小鼠含有更多的 2 型巨噬细胞,原代 A5;Kras 肿瘤细胞上调了调节巨噬细胞趋化和分化为 M2 巨噬细胞的细胞因子的表达。在胰腺癌细胞系中敲低 Atg5 会增加其迁移和侵袭能力,并在注射到小鼠后形成转移灶。在人类 PDAC 样本中,ATG5 水平较低与肿瘤转移和较短的生存时间相关。
在表达致癌性 Kras 的胰腺细胞中,Atg5 杂合缺失和蛋白水平降低促进肿瘤的发展,而 Atg5 纯合缺失则阻止肿瘤发生。在 PDAC 中改变自噬的治疗策略应考虑 ATG5 水平的影响,以避免耐药和高度侵袭性细胞的扩张。